Related Experiment Videos
Intrathecal neostigmine for post-cesarean section analgesia: dose response
J A Krukowski1, D D Hood, J C Eisenach
1Department of Anesthesia, The Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157-1009, USA.
Anesthesia and Analgesia
|June 1, 1997
Summary
Intrathecal neostigmine provided safe and effective postoperative pain relief for cesarean section patients, significantly reducing their need for morphine without impacting fetal well-being.
Area of Science:
- Anesthesiology
- Obstetrics
- Pain Management
Background:
- Intrathecal (IT) neostigmine demonstrates analgesic properties and enhances opioid efficacy.
- Investigating IT neostigmine's safety in obstetrics is crucial for potential clinical application.
Purpose of the Study:
- To evaluate the safety and efficacy of intrathecal neostigmine for postoperative analgesia in patients undergoing cesarean section.
- To assess the impact of IT neostigmine on fetal well-being and maternal pain management.
Main Methods:
- A dose-ranging, open-label study involving 24 term pregnant patients undergoing elective cesarean section.
- Patients received IT placebo or neostigmine (10, 30, 100 microg) followed by epidural lidocaine.
- Postoperative pain was managed with patient-controlled intravenous morphine.
Main Results:
- IT neostigmine did not adversely affect fetal heart rate or Apgar scores.
- Neostigmine significantly reduced 24-hour postoperative morphine consumption by 39% compared to placebo (50 vs. 82 mg).
- Analgesia was dose-independent and provided significant pain reduction for up to 10 hours post-surgery.
Conclusions:
- IT neostigmine offers a safe and effective method for managing post-cesarean section pain.
- The findings support further investigation into IT neostigmine for obstetric analgesia.
- Neostigmine reduces opioid requirements without compromising neonatal outcomes.